Premium
Combination Chemotherapy for Immature (Malignant) Teratomas of the Ovary
Author(s) -
Singh Pritam,
Yordan Edgardo L.,
Graham James R.,
Wilbanks George D.,
Slayton Robert E.,
Miller Alexander W.,
Ratnam S. S.
Publication year - 1987
Publication title -
asia‐oceania journal of obstetrics and gynaecology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.597
H-Index - 50
eISSN - 1447-0756
pISSN - 0389-2328
DOI - 10.1111/j.1447-0756.1987.tb00291.x
Subject(s) - vincristine , immature teratoma , cyclophosphamide , laparotomy , chemotherapy , ovary , medicine , regimen , combination chemotherapy , oncology , adjuvant chemotherapy , adjuvant , surgery , cancer , germ cell tumors , breast cancer
Immature (malignant) teratomas of the ovary without combination chemotherapy are highly fatal neoplasms. Within the last decade postoperative adjuvant combination chemotherapy has been shown to be highly effective and produced long term survival in patients with these tumours. The efficacy of a regimen containing vincristine, acti‐nomycin D and cyclophosphamide is reported with several patients alive free of disease at 5 to 10 years. The factors influencing prognosis, duration of therapy and role of second‐look laparotomy in immature teratomas are discussed.